R&D Partner Content 4th Mitochondrial Dysfunction Drug Development Summit Uncover mitochondrial pathogenic mechanisms to show clinical efficacy for regulatory success
Events Partner Content 2nd Mitochondria-Targeted Drug Development Summit Therapies for mitochondrial dysfunction
Oncology ASCO 2026: Three ADC approvals in five days, with Ken Keller... At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
